

Delivering beyond the liver

Next-generation LNP technologies to enable genetic medicines


Dominik Witzigmann, PhD

Co-Founder & President NanoVationTx



Market Dynamics | The next wave of genetic medicines will be enabled by delivery

1 Genetic medicines are entering a new growth cycle



\$100B+

Projected market¹
by mid 2030s

20%+


CAGR projection²
through next decade

2,000+

Clinical programs³
requiring delivery

¹⁻³ Aggregated public market forecasts across RNA therapeutics and CGT markets incl. fortunebusinessinsights.com, mediatechinsights.com, ASGCT Landscape Report

2 Delivery is the industry's limiting factor



Conventional LNP are trapped by the liver


Four critical pain points



Tissue
access



Safety/
Tolerability




Scalability/
Manufacturing



Intellectual
Property

3 NanoVation Tx is at the forefront



Technology

LNP for extrahepatic delivery

IP Portfolio

Broad, differentiated IP portfolio

Know-how

Decades of LNP expertise

**Accelerating the development
of genetic medicines**

Validated by global pharma | Built by pioneers | Positioned beyond the liver

Corporate Overview | From foundational innovation to next generation LNP delivery



Highly Cited
Researchers 2024

Founded by World Leaders



First-ever siRNA
drug **Onpattro**




First COVID-19 mRNA
vaccine **Comirnaty**



Pioneers of next-gen
LNP breakthroughs

Dominik Witzigmann | Pieter Cullis | Jayesh Kulkarni



Differentiated by Technology



Broad delivery
beyond the liver



Scalable
& cost-efficient



Strong IP
120+ patents



Clinically relevant in vivo CAR efficacy in NHP at
0.1 mg/kg without targeting ligand



Trusted by Global Biopharma



Broad applicability
across diseases



Collaborative
global partnerships



Partnership
with Novo Nordisk




Novo Nordisk bets \$600M biobucks on NanoVation's
ability to take genetic medicines beyond the liver


Built by pioneers. Designed to scale.

Technology Overview | Next-generation LNP enable the delivery beyond the liver


LNP Evolution Strategic Comparison



HSC editing




LT-HSCs




In vivo CAR

Increased blood circulation validated at different doses




$t_{1/2} < 1h$ vs $t_{1/2}$ 14-18h


IcLNP | 0.1 mg/kg



uLNP™



I.M. (24 hours)



Application-specific delivery rather than one-size-fits-all LNPs

What is your **delivery** challenge?

Partner with NanoVationTx to enable your genetic medicine beyond the liver.

d.witzigmann@nanovationtx.com